An expert outlines vision-preserving strategies for monocular high-risk GA, emphasizing early intervention and tailored therapy for safety and stability. Dr. Sambhara presents an 82-year-old monocular ...

An expert summarizes real-world GA management lessons, highlighting personalized imaging-guided care and patient-centered strategies to maintain vision stability. Dr. Sambhara closes with ...

A study reveals that lesion characteristics in geographic atrophy significantly influence growth rates, highlighting the need for targeted treatment strategies. The lesion characteristics of patients ...

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

Xelafaslatide (formerly ONL1204) is a small-molecule Fas inhibitor designed to protect key retinal cells from cell death that occurs across multiple retinal diseases and conditions such as geographic ...

Retina specialists share their perspectives on evolving anti-VEGF therapy, pipeline treatments, and strategies to enhance patient outcomes. As retinal care continues to advance, ophthalmologists are ...

Innovative retinal therapies are advancing through FDA trials, promising breakthroughs in treating various retinal diseases. The retina field continues to see significant developments in the FDA ...

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates. The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, ...

A panelist discusses how integrating clinical trial data with real-world experience, patient-centered care, and shared decision-making enables retina specialists to individualize treatment plans, ...

Belite Bio recently announced the acceptance of its New Drug Application (NDA) with priority review for tinlarebant by the Center for Drug Evaluation of China’s National Medical Products ...

Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.